Analyst Reco. Protagonist Therapeutics, Inc.

Equities

PTGX

US74366E1029

Real-time Estimate Cboe BZX Other stock markets 12:48:05 2024-06-06 pm EDT			5-day change	1st Jan Change
33.8 ^USD	-0.69%		+23.01%	+48.65%

May. 07	Protagonist Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 03	Protagonist Therapeutics Insider Sold Shares Worth $707,750, According to a Recent SEC Filing	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Protagonist Therapeutics Insider Sold Shares Worth $707,750, According to a Recent SEC Filing	Apr. 03	MT
JPMorgan Adjusts Price Target on Protagonist Therapeutics to $37 From $34, Maintains Overweight Rating	Feb. 28	MT
Capital One Starts Protagonist Therapeutics With Overweight Rating, $32 Price Target	23-10-30	MT
JPMorgan Lowers Protagonist Therapeutics' Price Target to $34 From $36, Keeps Overweight Rating	23-09-25	MT
JMP Securities Raises Protagonist Therapeutics' Price Target to $35 From $28, Keeps Market Outperform Rating	23-07-06	MT
HC Wainwright Adjusts Price Target on Protagonist Therapeutics to $38 From $33, Maintains Buy Rating	23-03-16	MT
JMP Securities Adjusts Price Target on Protagonist Therapeutics to $28 From $31, Maintains Market Outperform Rating	23-03-16	MT
JMP Securities Adjusts Price Target on Protagonist Therapeutics to $31 From $21, Maintains Market Outperform Rating	23-03-08	MT
HC Wainwright Lowers Price Target on Protagonist Therapeutics to $33 From $50, Maintains Buy Rating	22-11-10	MT
JMP Securities Reinstates Protagonist Therapeutics at Market Outperform With $21 Price Target	22-08-25	MT
Piper Sandler Adjusts Price Target on Protagonist Therapeutics to $35 From $60, Reiterates Overweight Rating	22-05-18	MT
SVB Leerink Adjusts Protagonist Therapeutics' Price Target to $30 from $50, Keeps Outperform Rating	22-05-05	MT
BTIG Initiates Protagonist Therapeutics at Buy With $55 Price Target	22-02-11	MT
JMP Securities Adjusts Price Target on Protagonist Therapeutics to $70 From $60, Keeps Market Outperform Rating	21-11-15	MT
PROTAGONIST THERAPEUTICS : JMP Securities Adjusts Price Target on Protagonist Therapeutics to $60 From $47, Maintains Market Outperform Rating	21-10-13	MT
PROTAGONIST THERAPEUTICS : JMP Securities Adjusts Price Target on Protagonist Therapeutics to $47 From $55, Maintains Market Outperform Rating	21-10-12	MT
PROTAGONIST THERAPEUTICS : SVB Leerink Adjusts Protagonist Therapeutics' Price Target to $50 from $35, Keeps Outperform Rating	21-10-12	MT
PROTAGONIST THERAPEUTICS : JPMorgan Upgrades Protagonist Therapeutics to Overweight From Neutral, Sets Price Target at $55	21-10-12	MT
ANALYST RECOMMENDATIONS : Cigna, Halliburton, Nike, Nio, Trex...	21-10-12
PROTAGONIST THERAPEUTICS : Northland Capital Markets Upgrades Protagonist Therapeutics to Outperform Rating From Market Perform, Lifts Price Target to $40 From $25	21-10-11	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Protagonist Therapeutics, Inc.

Equities

PTGX

US74366E1029

Analyst Reco.

Filters